# Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Source: https://onco.cc/trials/nct07517198/  
OnCo record `nct07517198` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of REC-4539 run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., now recruiting.

## Summary

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors is a phase 1 interventional study registered as NCT07517198 by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., with 40 participants planned, started 2026-04-13. Conditions recorded: Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer and Triple-negative Breast Cancer (TNBC). Interventions recorded: EXS74539. OnCo files the registry's Hepatic Cancer under its liver cancer page.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07517198
- Phase: 1
- Setting: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors
- Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07517198: https://clinicaltrials.gov/study/NCT07517198

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [REC-4539](https://onco.cc/drugs/rec-4539/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)

---
JSON: https://onco.cc/api/v1/entities/nct07517198.json